Pediatric oncology provider views on biopsying solid tumors in children with relapsed or refractory disease for the purpose of genomic profiling.
Barrie Cohen(Rutgers, The State University of New Jersey), Jonathan Gill(Albert Einstein College of Medicine), Richard Görlick(The University of Texas MD Anderson Cancer Center), Michael Roth(The University of Texas MD Anderson Cancer Center), David S. Geller(Albert Einstein College of Medicine), Katherine A. Janeway(Harvard University), Stacy W. Gray(City of Hope), Bang H. Hoang(Albert Einstein College of Medicine), Jonathan M. Marron(Dana-Farber/Boston Children's Cancer and Blood Disorders Center)
Cited by 2
Related Papers
K <sup>+</sup> Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
|Science|2011|983
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
|Nature Medicine|2014|571